Riccardo Lolatto

Nov 18, 2024 | mdpi.com | Angelo Roberto Raccagni |Riccardo Lolatto |Flavia Passini |Lovel Lisac

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Apr 26, 2024 | mdpi.com | Angelo Roberto Raccagni |Alessandro Mancon |Sara Diotallevi |Riccardo Lolatto

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Dec 18, 2023 | mdpi.com | Giovanni Mori |Sara Diotallevi |Francesca Farina |Riccardo Lolatto

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Sep 18, 2023 | dovepress.com | Diana Canetti |Laura Galli |Riccardo Lolatto |Silvia Nozza

Introduction A fixed combination of bictegravir/emtricitabine/tenofovir alafenamide (BFTAF, Biktarvy®), an HIV integrase strand transfer inhibitor (InSTI) associated with two nucleoside reverse transcriptase inhibitors, has been available in Italy since June 2019 for the treatment of people living with HIV infection (PLWH).1 It represents a complete single-tablet antiretroviral therapy (ART) to be taken every 24 hr, both with food and on an empty stomach, which presents very few drug...

Aug 24, 2023 | mdpi.com | Angelo Roberto Raccagni |Riccardo Lolatto |Flavia Passini |Sara Diotallevi

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticleby 1,†, 1,*,†, 2, 2, 1, 1, 1, 1, 1, 1,2 and 1,2 1Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy2Infectious Diseases Unit, San Raffaele Scientific Institute, 20132 Milan, Italy*Author to whom correspondence should be addressed. †These authors contributed equally to this work.